Prota Therapeutics Pty Ltd Secures $32M in Series A Funding for Breakthrough Allergy Treatment Development

Prota Therapeutics Pty Ltd, an innovative Australian biotech company founded in 2016, is thrilled to announce that it has successfully raised AUD $32 million in its latest funding round. This substantial investment marks a significant milestone in Prota's mission to develop and commercialize cutting-edge combination probiotic allergen oral immunotherapy treatments. With an exclusive license to patented probiotic food immunotherapy technology developed at the Murdoch Children’s Research Institute (MCRI), Prota is at the forefront of creating groundbreaking solutions for patients suffering from food allergies. Notably, this Series A funding saw contributions from OneVentures, a premier Australian venture capital firm, which secured AUD $15 million from its Healthcare Fund III, complemented by an essential AUD $5 million infusion from the Australian Commonwealth Government’s Biomedical Translation Fund. This infusion of capital will propel Prota's clinical program, focusing on their promising PRT100 treatment for peanut allergies. The funding will also support the development of scalable and compliant Good Manufacturing Practices (cGMP) processes vital for product manufacturing and is set to facilitate productive discussions with regulatory agencies. As Prota gears up for a large-scale pivotal Phase 3 efficacy and safety study, this funding not only reinforces the company’s commitment to addressing food allergies through innovative therapy but also exemplifies the growing confidence in the biotech sector as a driver of critical healthcare solutions. The future looks bright for Prota Therapeutics as they pave the way for life-changing treatments in the realm of allergic disorders.